Vivecon (MP-9055)

According to developer Myriad Genetics MP-9055 (Vivecon), an experimental HIV maturation inhibitor, is entering phase IIA clinical trials in antiretroviral-naive HIV-positive patients. 

Completed phase I dose-ranging studies involving 55 HIV-negative individuals showed that the drug was safe. No serious side-effects were reported, nor were there any significant changes in blood chemistry or heart function as measured by ECG.

The phase I study also showed that the doses of Vivecon studied achieved levels in the blood capable of inhibiting HIV when dosed with food. Preliminary laboratory tests have already suggested that the drug has an anti-HIV effect, including against virus that is resistant to drugs from both the non-nucleoside reverse transcriptase and protease inhibitor classes.

Vivecon will now enter phase IIA clinical trials to further establish safety, efficacy, and pharmacokinetics.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.